Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Keros Therapeutics, Inc. (KROS) vs ProQR Therapeutics N.V. (PRQR)

Keros Therapeutics, Inc. and ProQR Therapeutics N.V. are both Biotechnology companies. Keros Therapeutics, Inc. and ProQR Therapeutics N.V. are of similar size ($236.1M and $229.0M). ProQR Therapeutics N.V. grew revenue faster over the last twelve months: 19.7% against −84.6%. Keros Therapeutics, Inc. has the higher net margin (0.00% vs −228.7%) and the lower return on invested capital (−1,345.3% vs 0.00%). Across the 16 metrics below, Keros Therapeutics, Inc. leads on 13 and ProQR Therapeutics N.V. on 3.

Valuation

Metric KROS PRQR Biotechnology median
P/E n/m n/m 7.88
P/S 6.97 8.45 11.47
P/B 0.88 1.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.26 n/m 0.74
EV/Sales (0.79) 2.60 10.73
Earnings yield (31.68%) (27.88%) (28.84%)
Free cash flow yield (20.97%) (31.63%) (23.03%)

Profitability

Metric KROS PRQR Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (233.33%) 0.00%
Net margin 0.00% (228.71%) 0.00%
Free cash flow margin 0.00% (267.36%) 0.00%
Return on equity (17.16%) (58.29%) (57.72%)
Return on assets (15.92%) (31.53%) (49.22%)
Return on invested capital (1,345.30%) 0.00% 0.00%

Growth

Metric KROS PRQR Biotechnology median
Revenue growth (TTM) (84.55%) 19.72% 5.64%
EPS growth (last fiscal year) 146.00% (28.57%) —
Revenue growth, 5-year CAGR 89.45% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KROS PRQR Biotechnology median
Debt to equity 0.00 0.06 0.00
Current ratio 21.96 3.49 4.73
Net debt to EBITDA (4.16) 2.15 0.96

Dividend

Metric KROS PRQR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric KROS PRQR Biotechnology median
Market cap 229.00m 236.13m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack